When do biologic drug patents expire and when will biosimilars launch?

US Patent 10,099,019 air-intake actuated nasal delivery device and method: claim scope, validity risk, and competitive patent landscape

US 10,099,019 is a device-and-method patent family built around an air-triggered, valve-controlled mechanism that delivers a predetermined nasal dose for a predetermined time window, where the trigger is actuated by the subject’s inhalation through a mouthpiece. The independent claim is drafted broadly across substance types (drug or vaccine), pressurization modes (spring or ambient-air pressurized spring/compressed air concepts), delivery time control, and multiple dependent claim “feature add-ons” (membrane, pulsation/sequencing, nozzle diameter affecting dose-duration, dosing compartments, cap/sterilization breakable at pressure, refill from external container, and dosing indicators).

From a patentability and freedom-to-operate (FTO) perspective, the estate’s critical risk is that much of the concept space is functionally known in the art: nasal delivery systems, breath-activated triggers, valve toggling, and dose-metering mechanisms are recurring themes in drug delivery device patents. The highest leverage for enforcing US 10,099,019 will be narrowing claim construction to the specific architecture and sequence requirements in the independent claims (air intake through mouthpiece triggers valve reconfiguration from inactive to active for a predetermined period, and delivery is “momentarily pressurized and delivered” upon activation), plus the dependent claim constraints that correlate to concrete structural features.

What this means operationally

If a competitor’s device does not require mouthpiece-triggered inhalation, does not include an inactive/active valve architecture toggled by the inhalation, or does not deliver a momentarily pressurized dose in a controlled time period, it is outside the strongest literal core.
If a competitor uses a different activation mechanism (manual button, electronic actuator, environmental pressure sensor, nostril airflow trigger without mouthpiece), it creates clean non-infringing design-arounds.
If a competitor uses the same high-level concept but differs in the pressurization chain (for example, no spring compression or no “momentarily pressurized” dosing pulse on valve activation), the claims become vulnerable to both non-infringement arguments and prior-art invalidity attacks.

What are the independent claim 1 elements in US 10,099,019, and which parts are most enforceable?

Claim 1 sets a “breath-to-nose” metering sequence with an inactive/active valve toggling mechanism. The independent claim is anchored by five functional/structural pillars.

1) Air-intake activation path: mouthpiece inhalation triggers valve reconfiguration

Trigger mechanism is “activated by means of said subject intaking air through said mouthpiece.”
Trigger reconfigures the valve from inactive to active for a predetermined period of time in response to intake.

Enforceability hinge: Many devices claim “breath-activated” triggering, but the claim ties activation specifically to inhalation through a mouthpiece (not through a nose interface) and requires valve configuration toggling (inactive to active and vice versa).

2) Valve architecture with at least two configurations

Valve is mechanically connectable to container.
Valve has active configuration enabling delivery of a predetermined amount and inactive configuration preventing delivery of that predetermined amount.

Enforceability hinge: The “inactive configuration prevents delivery” is an easy-to-apply infringement discriminator. If a competitor’s valve is always partially open, uses a continuous leak/flow, or uses dosing based on flow rate without a “prevent delivery” inactive state, the literal fit weakens.

3) Nosepiece fluid communication: container → valve → nosepiece → nasal cavity

Nosepiece is in fluid communication with container via the valve.
Upon activation, the substance is momentarily pressurized and delivered to nasal cavity.

Enforceability hinge: Claims can be read strictly as requiring the valve to establish the fluid communication path controlling the dose pulse. Systems that meter downstream at the nozzle without fully toggling the upstream valve may avoid infringement.

4) Dose delivery is “momentarily pressurized” upon activation

“Upon activation of said trigger mechanism said substance is momentarily pressurized and delivered from said container.”

Enforceability hinge: “Momentarily pressurized” is a technical phrase that can be argued narrowly. Systems delivering by aspiration, capillary flow, nebulization without a discrete pressurization pulse, or purely gravity-fed delivery will be fact-sensitive.

5) Time window constraint

Active configuration lasts for a predetermined period in response to air intake.

Enforceability hinge: This supports a strong attack on systems that deliver while the user breathes continuously, or deliver fixed volumes regardless of time gating by an independent timed mechanism rather than response to intake.

How do dependent claims 2–6 narrow pressurization and activation mechanics?

Dependent claims define concrete structural embodiments that can become both:

enforcement hooks for a specific competitor design, and
validity weaknesses if prior art contains the same features.

Claim 2: spring-compressed pressurization

Substance momentarily pressurized by “spring being compressed.”

Claim 3: ambient air in device pressurized by spring and delivered

“Ambient air present in said device being pressurized by spring and delivered with said substance.”

Key issue: Claims 2 and 3 target variations of the pressurization chain. If prior art teaches a breath-activated nasal sprayer that uses a spring-loaded piston or compressible air chamber, these dependents may be vulnerable. If competitors avoid spring compression, they can drop outside the “spring” subset but still fall within claim 1 if claim 1’s “momentarily pressurized” is satisfied by other pressurization.

Claim 5: valve returns to inactive when intake ceases

Synchronization with cessation is an additional timing feature.

Claim 6: flexible membrane coupled to valve

Membrane relocated when subject takes in air; valve opens.

Critical practical point: Membrane actuation is a common “pressure/vacuum flap” approach. If a competitor’s trigger uses a different mechanism (gear latch, electromagnet, piezo, microvalve actuated electrically), claim 6 is avoidable.

What do claims 7–15 cover (dose compartment, synchronization, pulsation sequencing, nozzle/nozzle-diameter control, sterilization cap, refill, and indicators)?

Claim 7: intermediate compartment dosing

Intermediate compartment filled from container with predetermined amount; delivery from intermediate compartment.

Design-around: Competitors using direct metering from a reservoir without an intermediate metering compartment can avoid claim 7 while still potentially practicing claim 1.

Claim 8: synchronizable trigger operation with intake

Adds timing control synchronization.

Claim 9: pulsation mechanism delivering according to pulse sequence

Pulsation mechanism reconfigures valve in sequence of pulses, each with predetermined length.
Valve releases predetermined amount according to sequence.

Validity and enforceability: Pulse sequencing and timed valve cycling are common in inhaler actuation patents. This dependent may narrow infringement only if the competitor literally uses pulse-based valve reconfiguration to deliver doses in a defined sequence (and not a single dose pulse).

Claim 10: spray nozzle diameter influences predetermined period of time

Nosepiece fluid communication via spray nozzle; diameter influences period.

This is a technical constraint that can create construction disputes (how diameter “influences” time). Competitors can design nozzle diameter without mapping to time gating, aiming to defeat literal “influences said predetermined period of time.”

Claims 11–13: pressurization builds in device; sterilization cap breakable at pressure

Upon reconfiguration pressure built within device.
Cap for sterilization purposes with an opening; cap breakable upon reaching predetermined pressure.

Enforcement: Cap-breakable-at-pressure is a niche feature. Most commercial systems will not have breakable sterilization caps, making this largely a validity shield for specific embodiments and a narrow infringement hook.

Claim 14: container refill from external container

Container connectable to external container; external container fills container with predetermined dose.

Claim 15: transparent window indicating remaining amount

Indicator window.

These are commercially common device features and likely appear in prior art. Their presence strengthens commercial realism but may not add much enforceability unless a competitor copies the entire combination.

How broad are the substance, vaccine, and formulation-dependent claims (16–20), and what does that do to invalidity risk?

Claim 16: substance group includes broad drug classes

Includes anti-angiogenesis agents, antisense, NSAIDs, opioids, growth hormone pathway drugs, insulin, nicotine, COX-II inhibitors, etc., plus “any combination thereof.”

Claim 17–18: vaccine scope plus disease treatment lists

These dependents recite a sweeping list of vaccine antigen types and delivery into disease indications, including bacteria/virus vectors, subunit protein/peptide/polysaccharides, toxoids, live attenuated reassortants, and many organisms. Claim 18 expands to specific disease and CNS examples.

Claim 19: therapeutic substance list

Extends across analgesics, anesthetics, anti-depressants, antihistamines, immunosuppressives, proteins/peptides, monoclonal antibodies, oils, amino acids, vitamins, etc.

Claim 20: dosage form enumeration

Powder, granules, capsules, tablets, paste, cream, gel, ointment, foam, lotion, suspension/solution/emulsion, patch, stick, nasal spray/buccal spray, mouthwash, aerosol from Venturi effect, and drink.

Critical analysis:

These dependents do not add a delivery architecture constraint; they add breadth of substance/form.
In enforceability terms, breadth helps cover many product lines without changing device mechanics.
In validity terms, such breadth increases the risk that prior art nasal delivery devices with breath activation existed for at least one of these categories and that the claim’s application to other categories could be argued as unsupported by specific technical differences.
Courts often treat generic “intended use” and broad genus lists as difficult to distinguish over prior art unless the device interaction with the substance is technically specified.

Is there a method claim that tracks the device claim, and where is infringement most likely?

Claims 21–39 are method counterparts, essentially:

provide the same device architecture,
place nosepiece near nose,
place mouthpiece in mouth,
subject takes air through mouthpiece,
trigger activates valve active for predetermined period,
upon activation substance is momentarily pressurized and delivered to nasal cavity, plus the same narrowing dependents.

Infringement likelihood

Product makers can be targeted for device claim infringement.
Method claims can be asserted against both manufacturers and users depending on who performs the steps. For an at-home consumer device, method claims may be harder to enforce against end users, but licensing and settlements typically treat them as leverage.

What key non-infringement design-arounds can competitors use against the claim 1 core?

Activation mechanism alternatives

Replace mouthpiece inhalation trigger with nose-only airflow sensing or nasal pressure trigger.
Replace breath-trigger with manual actuation, electronic actuator, or sensor-driven microcontroller triggered by time or exhalation instead of intake through mouthpiece.

These target the “intaking air through said mouthpiece” requirement and the valve reconfiguration “in response” to that intake.

Valve toggling structure

Use a continuously metering microfluidic flow path without a clear “inactive configuration preventing delivery of said predetermined amount.”
Use a pump that meters during activation but does not have a valve configuration that functionally prevents delivery when inactive.

This targets the “two configurations” and “inactive prevents delivery of said predetermined amount” language.

Pressurization chain

Deliver by aerosolization without “momentarily pressurized” dose pulse from a container upon valve activation.
Avoid discrete spring compression.

This targets claim 2/3 dependents and can also challenge claim 1 on “momentarily pressurized.”

Time gating

Deliver based on dose count independent of a predetermined intake-responsive period (for example, fixed bolus triggered by threshold sensor, not a predetermined period of active state).
Deliver while inhalation continues without a predetermined, intake-linked time window.

This targets the predetermined period constraint.

How strong is the patent estate likely to be versus prior art themes (breath-activated inhalers, nasal drug delivery, valve metering, and spring-loaded pressurization)?

A breath-triggered, valve-controlled nasal delivery concept lives at the intersection of several mature patent clusters:

dose-metering nasal sprays (pump, compressed air, metering),
breath-actuated inhalers (mouthpiece-based triggers),
valve switching mechanisms with active/inactive dosing,
spring-loaded actuators and pressurized chamber architectures.

Given that these clusters are well developed, the enforceability of US 10,099,019 will likely rise or fall on:

whether the claimed combination of mouthpiece inhalation → valve inactive/active reconfiguration → predetermined time window → momentary pressurization → nasal delivery was already disclosed, and
whether the “momentarily pressurized” and time-window features differentiate over known breath-activated nebulizers and nasal pumps.

In practical litigation posture, the broad substance and disease lists (claims 16–20, 17–19, 18) likely do not carry much novelty weight. Novelty, if any, is in the delivery mechanism sequence.

US 10,099,019: claims-to-design mapping for competitive FTO screening

Claim feature	What it covers in plain terms	Easy to design-around	Hard to design-around if present
Mouthpiece intake triggers	Inhalation through a mouthpiece actuates the trigger	Use nose-only sensing; remove mouthpiece trigger	If consumer must inhale through mouthpiece and that actuation triggers valve switching
Inactive vs active valve	Valve blocks delivery in inactive configuration	Use continuous microflow; avoid “inactive prevents delivery” behavior	If a valve state stops bolus delivery entirely then opens on inhalation
Predetermined period active	Valve stays in active for fixed time window responsive to intake	Deliver dose immediately without time-window active state	If valve remains active for a time tied to intake events
Momentarily pressurized delivery	Discrete pressurization pulse on activation	Gravity/aspiration-only delivery; continuous aerosol	If device creates a discrete pressurization upon activation
Spring compression	Pressurization uses spring	Use electro-pneumatic actuation without spring	If a spring-loaded chamber/piston is integral
Flexible membrane	Membrane mechanically linked to valve	Use electronic/pneumatic actuator or different mechanical latch	If membrane relocation opens valve on inhalation
Intermediate compartment	Dose metered into intermediate chamber	Meter directly from reservoir to nozzle	If intermediate chamber meters predetermined volume
Pulsation sequence	Valve cycles in sequence of pulses	Single open-close bolus	If valve toggles multiple times with set pulse lengths
Nozzle diameter influences time	Nozzle geometry tied to predetermined period	Use geometry not linked to time gating	If nozzle diameter explicitly affects delivery time and is claimed that way
Breakable sterilization cap	Cap breaks at threshold pressure	Avoid breakable cap/sterilization mechanism	If sterilization uses breakable cap at pressure

Where the litigation and regulatory leverage would concentrate if this were asserted

Because the claim suite is device-centric, enforcement would most likely focus on:

consumer-use devices (nasal delivery) with breath activation through a mouthpiece,
devices using valve states with inactive prevention and active timed delivery,
systems with discrete dose pressurization pulses on inhalation.

Regulatory angle: The device itself does not map to an FDA Orange Book drug listing unless coupled to an approved drug product with listed device and drug components. The enforcement posture would typically be patent-driven rather than exclusivity-driven, since the patent claims do not appear to be tied to a specific drug’s NDA/ANDA listing.

Key Takeaways

Claim 1 is built on a specific sequence: mouthpiece inhalation actuates a trigger that toggles a valve from inactive to active for a predetermined intake-responsive period, delivering a momentarily pressurized predetermined nasal dose.
Dependent claims add mechanical specificity (spring compression, ambient-air pressurized by spring, flexible membrane, intermediate compartment, pulse sequencing, nozzle diameter influencing delivery time, and a breakable sterilization cap).
Substance and disease breadth (claims 16–20 and 17–19) are expansive but likely contribute less to novelty than the device actuation and dosing mechanics.
Design-arounds are most available at three points: remove mouthpiece-based breath activation, remove the inactive/active timed valve behavior, or remove the discrete pressurization pulse architecture.

FAQs

1) What single feature most distinguishes US 10,099,019 from generic nasal sprays?
The inactive/active valve that is reconfigured for a predetermined period in response to air intake through a mouthpiece, with momentarily pressurized delivery upon activation.

2) Can a competitor infringe if the device is nose-triggered rather than mouthpiece-triggered?
Literal infringement risk drops if there is no activation by air intake through a mouthpiece as claimed.

3) Are the long lists of drugs and vaccines in dependent claims likely to broaden enforceability?
They broaden coverage of what “substance” can be delivered, but they also increase invalidity risk if the delivery mechanism lacks novelty versus prior breath-activated delivery devices.

4) Which dependent claims are most useful for pinpoint licensing or targeted litigation?
Claims tying to specific mechanical implementations: spring pressurization (2), flexible membrane triggering (6), intermediate compartment dosing (7), pulse sequencing (9), and breakable sterilization cap (12–13).

5) What is the highest-value FTO search theme around this patent?
Breath-activated, mouthpiece-triggered metered nasal dosing devices with valve switching and timed delivery pulses using spring-loaded or chamber pressurization.

References

No external sources were provided in the prompt for US 10,099,019 filing data, assignees, prosecution history, cited art, or FDA/Orange Book linkages.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	June 21, 1989	⤷ Start Trial	2037-01-25
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	January 23, 2015	⤷ Start Trial	2037-01-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Summary for Patent: 10,099,019